PrEP Update

How generic medicines are helping re-shape pre-exposure prophylaxis (PrEP)

Presented by: Robert Pilarski, MD and Michael Fanous, PharmD, RPh


Do you or your patients have questions about the available options to prevent and treat HIV?

We invite you to join this live multidisciplinary webinar focused on PrEP as part of an effective strategy to prevent the risk of the sexual transmission of HIV and options to overcome potential cost barriers.

Presenters will talk about clinical research on the efficacy of PrEP and the strong correlation to adherence. Through case examples, they will offer their guidance on identifying appropriate candidates for PrEP treatment and best practices to promote successful outcomes.

This program will also explore the interchangeability of generic and brand name products and how the use of generic antiretrovirals can provide financial benefits to the patient and the Canadian healthcare system.

Join your colleagues for a live webinar.

Following this one-hour presentation, you will have the opportunity to participate in an interactive Q&A with the presenters.
To help accommodate your schedule, several date and time options are available for the English version of this webinar.
To view date and time options for the French version please click here.


December 14, 2017

2:20 PM EDT


February 20, 2018

12:00 AM EDT


March 20, 2018

12:00 AM EDT


April 20, 2018

12:00 AM EDT

Registration is required to complete your accreditation.



Robert Pilarski, MD


Dr. Robert Pilarski graduated from the Sherbrooke University Medical School, and completed his residency in Family Medicine at the same institution. He has been an HIV and Aids Prevention activist, and has pursued an epidemiological interest in HIV and STI since his family medicine residency. Dr. Pilarski delivers primary health care at the Clinique de la medicine urbaine du Quartier Latin, the largest HIV/STI clinic in the province of Quebec, and also participates in HIV clinical research. He implements HIV treatment as prevention and is one of the pioneers of pre-exposure prophylaxis also known as PreP.

Michael Fanous, PharmD, RPh


Dr. Michael Fanous is an AIDS activist who happens to also be a HIV pharmacist in Toronto primarily serving the LGBTQ community. Michael began working in Canada’s largest HIV clinic, Maple Leaf Medical, over 15 years ago when he witnessed the challenges of managing patient’s antiretroviral therapy and the rise of Undetectable status as a hallmark of HIV treatment. Michael earned his Doctor of Pharmacy degree in 2008 from Union University in NY, and driven by experiences that he and many of his friends have had to overcome accessing gay-friendly and knowledgeable providers, began volunteering as a counsellor in Toronto’s Gay Village. As an activist, Michael continues in the fight against HIV/AIDS with improving HIV awareness, research projects, and opposing HIV-stigma. As a HIV pharmacist, Dr. Fanous advocates for access to care through, the only LGBTQ-owned pharmacy practice in Ontario devoted to helping people navigate the complexities of accessing HIV treatment, PrEP, PEP and Hepatitis C medications.

Learning objectives

Learning Objectives

  1. Describe the efficacy of oral emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) in providing protection against the acquisition of HIV infection
  2. Determine how to identify an at-risk person who would be an appropriate candidate for pre-exposure prophylaxis (PrEP)
  3. Explore best practices for the consistent and correct use of PrEP as an effective strategy to help prevent the sexual transmission of HIV
  4. Discuss the importance of adherence to maximize PrEP efficacy
  5. Understand the fundamental principles and benefits of bioequivalence testing
  6. Review the cost and comparative bioavailability studies between generic and brand-name FTC/TDF

This Group Learning program has been certified by the College of Family Physicians of Canada and the Ontario Chapter for up to 1.5 Mainpro+ credits.

The Canadian Council on Continuing Education in Pharmacy has accredited this program for 1.5 CEUs.
Activity number: 1160-2017-1993-L-P. Date accredited: March 16, 2017. Accreditation expiry date: March 16, 2018

This program is supported in part by an educational grant from Teva Canada.

Invite a colleague

Help empower physicians and pharmacists in your professional network to answer common questions about generics.

Add another colleague


* = Required

You may also be interested in the following accredited program(s).


Health Canada’s Approved Generic Medicines:

The Basis for Trust by Patients, Professionals and Providers

Presented by Dr. Jake Thiessen, PhD

  • Be better prepared to answer your patient’s questions about the interchangeability of generic and brand name drugs
  • Review the economic implications of drug selection on our healthcare dollars